An2 Therapeutics, Inc. · NASDAQ:ANTX
Readnour Robin Shane sold 16,119 An2 Therapeutics, Inc. shares (Form 4)
Traded Sep 3 to Sep 8, 2026 · Filed Sep 8, 2026
From Sep 3 to Sep 8, 2026, Readnour Robin Shane (Director) sold 16,119 An2 Therapeutics, Inc. shares at an average US$6.04 for US$97,341 under a trading plan, leaving 625,350 shares. Filed Sep 8, 2026 (Form 4).
- Sold
- 16,119 shares
- Price
- US$6.04 average (US$6.02 to US$6.07)
- Value
- US$97,341
- Holding after
- 625,350 shares (held indirectly)
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | Common Stock | Sale | 2,877 | US$6.07 | 562,715 | Indirect |
| Sep 3, 2026 | Common Stock | Sale | 3,223 | US$6.07 | 630,644 | Indirect |
| Sep 8, 2026 | Common Stock | Sale | 4,725 | US$6.02 | 557,990 | Indirect |
| Sep 8, 2026 | Common Stock | Sale | 5,294 | US$6.02 | 625,350 | Indirect |
Source
Related
- An2 Therapeutics, Inc.
- Readnour Robin Shane
- An2 Therapeutics, Inc. shareholders
- Form 4 · Readnour Robin Shane · Sep 11, 2026
- Form 4 · Readnour Robin Shane · Aug 19, 2026
- Form 4 · Aziz Kabeer · Oct 13, 2026
- Form 4 · Martin Patricia A. · Oct 13, 2026
- Form 4 · Marks Gilbert Lynn · Oct 13, 2026
- Form 4 · Trenor Cameron C. III · Sep 16, 2026
- Form 4 · Williams Sarah Joanne · Sep 4, 2026